Drug Profile


Alternative Names: PR 350; RP 343

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kyoto University; POLA PHARMA
  • Developer POLA PHARMA; Shuttle Pharmaceuticals
  • Class Imidazoles; Radiosensitisers
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Research Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 15 Aug 2017 Doranidazole licensed to Shuttle Pharma in USA
  • 15 Aug 2017 Dranidazole licensed to Shenzhen Main Luck Pharmaceuticals in China
  • 15 Aug 2017 Early research in Non-small cell lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top